Kathleen Cantagallo

Shackelford Pharma Inc. is a clinical stage biopharmaceutical company formed to develop medicines for neurological diseases with significant unmet patient needs. Founded by Dr . Alan Shackelford and leading medical industry executives, Shackelford Pharma is leveraging Dr. Shackelford’s real-world clinical experience to develop novel therapies for specific indications targeting the endocannabinoid system.

RheoTek Medical focuses on developing needle-free injector technology that aims to make injections less painful and enhance the precision of depth and dispersion on the face. Their innovative technology delivers precise injections into pre-determined tissue depths based on the force profile utilized. This ensures reliable dispersion of medication throughout the target tissue, thereby increasing efficacy.

Retired Senior Executive providing expert consulting services to both start-up and well established companies working in the Life Science Industry. Start-up: strategic support for commercializing their early – stage life technology. Providing exposure to the funding community (grants & investors) and development of a funding roadmap to take the technology from bench to marketplace. The aim is to reduce the business risk , increase the potential attractiveness to follow-on investment by established life science companies and private investors. Established life science companies: bring strong experience in all phases of drug development including: - Strategic Leadership (Strategy and Execution) - Portfolio Management - Drug Development (clinical, regulatory, pharmaceutical development, and commercialization) - Business development licensing opportunity evaluation

Business Advisor to the Phase 2 Ventures & QED incubator programs, providing mentoring and coaching to academic researchers (and their projects), helping them commercialize promising technologies.

A startup company, out of Rutgers University, that has developed a platform technology; specifically, the first synthetic transcription factor (TF) platform to manipulate cellular processes. The manipulation of cellular processes has an enormous potential in the field of regenerative medicine and can be applied to any therapy or field where modulating gene expression is desired. NanoScript is the first nanomaterial-based platform that mimics natural TFs and binds to endogenous DNA to regulate gene expression at the transcriptional level. To generate different NanoScript constructs, the DNA binding domain on NanoScript can easily be redesigned to activate different target genes. Therapeutic focus has been on hearing loss, traumatic brain injury and spinal cord injury. Effort for this early phase project has been on the acquisition of grant funding to further develop the technology aiming at improved technical feasibility.

I was accountable for the strategic and operational leadership of the cross-functional Global Product Team delivering the successful global product development, regulatory approval, commercialization and launch of Movantik aligned to the global brand strategy through the brand’s life cycle. Key accountabilities include: • Leadership of a global product team, developing and presenting investment cases for governance endorsement to ensure smooth and efficient transition from early development, movement through late development, global submissions, securing approval and launch. Key capabilities and attributes: - Entrepreneurial in problem solving, and maximizing opportunities for the brand through shaping and driving coherent, ambitious and a deliverable product strategy - Identify opportunities for the product strategy, driving decisions by coalescing diverse internal and external stakeholders’ interests. - Simplify the complex, anticipates obstacles and barriers. I work around them by integrating robust scientific, regulatory, competitive intelligence, KOL and payer insights. - Ensure appropriate Governance and Compliance and protects Company Rights, Data and Intellectual Property through the development and execution of the publication and Public Relations strategy for Movantik · Approve all external information on Movantik · Manage and protect the Intellectual Property (IP) assets in consultation with IP and legal experts including leadership of the Patent, Regulatory and Legal Defense Team · Leadership of cross functional issues management teams and Advisory Committee meeting preparations

Responsible for leading a cross-functional team for the delivery of emerging psychiatry and degenerative disease (Schizophrenia, Bipolar Disorder, Depression/Anxiety, MS & Parkinsons) across all ranges of the early portfolio (preclinical through phase 2) on-time, with quality and on-budget within agreed scope of work.

Responsible for facilitating the management of the Neuroscience Therapeutic Area in line with the new business processes and R&D strategic objectives to achieve greater efficiency and effectiveness internally through both the Development and Discovery Organizations.